In the last 12 months, insiders at Xenon Pharmaceuticals made open-market purchases of $1.68 million (45K shares) and open-market sales of $21.97 million (381.59K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Mohammad Azab | Director | 74,225 | 0 | 74,225 | 30.2% | 20 Dec, 2023 |
| 2 | Ian Mortimer | President Ceo | 49,923 | 0 | 49,923 | 20.3% | 01 Oct, 2026 |
| 3 | Dawn Svoronos | Director | 31,373 | 0 | 31,373 | 12.8% | 03 Sep, 2026 |
| 4 | Gary Patou | Director | 24,896 | 0 | 24,896 | 10.1% | 08 Jun, 2026 |
| 5 | Thomas Patrick Kelly | Chief Financial Officer | 22,500 | 0 | 22,500 | 9.2% | 16 Oct, 2026 |
| 6 | James R. Empfield | Evp, Drug Discovery | 10,000 | 0 | 10,000 | 4.1% | 16 Aug, 2022 |
| 7 | Sherrington Robin | Evp, Strategy Innovation | 8,398 | 0 | 8,398 | 3.4% | 08 Mar, 2024 |
| 8 | Andrea Difabio | Chief Legal Officer | 7,301 | 0 | 7,301 | 3.0% | 13 Mar, 2026 |
| 9 | Simon N. Pimstone | Ceo | 6,000 | 0 | 6,000 | 2.4% | 01 Jun, 2023 |
| 10 | Patrick Machado | Director | 2,645 | 0 | 2,645 | 1.1% | 03 Jun, 2026 |
| 11 | Justin D. Gover | Director | 2,645 | 0 | 2,645 | 1.1% | 03 Jun, 2026 |
| 12 | Elizabeth A. Garofalo | Director | 2,645 | 0 | 2,645 | 1.1% | 03 Jun, 2026 |
| 13 | Steven Gannon | Director | 1,870 | 0 | 1,870 | 0.8% | 13 Aug, 2026 |
| 14 | Gillian Cannon | Director | 1,455 | 0 | 1,455 | 0.6% | 08 Jun, 2026 |
| 15 | Christopher John Kenney | Chief Medical Officer | 2 | 0 | 2 | 0.0% | 31 Aug, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 15 Oct, 2026 | Thomas Patrick Kelly | Chief Financial Officer | Acquired M | 7,500 | — | — | 22,500 | Direct |
| 15 Oct, 2026 | Thomas Patrick Kelly | Chief Financial Officer | Disposed M | 7,500 | $0.00 | $0 | 22,500 | Direct |
| 30 Sep, 2026 | Thomas Patrick Kelly | Chief Financial Officer | Acquired P | 15,000 | $37.32 | $559.74K | 15,000 | Direct |
| 30 Sep, 2026 | Ian Mortimer | President Ceo | Acquired P | 30,000 | $37.38 | $1.12Mn | 49,923 | Direct |
| 01 Sep, 2026 | Dawn Svoronos | Director | Acquired M | 5,144 | $8.15 | $41.92K | 31,373 | Direct |
| 01 Sep, 2026 | Dawn Svoronos | Director | Disposed M | 5,144 | $0.00 | $0 | 0 | Direct |
| 28 Aug, 2026 | Christopher John Kenney | Chief Medical Officer | Disposed S | 6,368 | $60.17 | $383.15K | 702 | Direct |
| 28 Aug, 2026 | Christopher John Kenney | Chief Medical Officer | Disposed S | 700 | $60.98 | $42.68K | 2 | Direct |
| 11 Aug, 2026 | Steven Gannon | Director | Disposed S | 10,000 | $64.06 | $640.55K | 1,870 | Direct |
| 05 Jun, 2026 | Gillian Cannon | Director | Disposed S | 1,190 | $53.14 | $63.24K | 1,455 | Direct |
| 05 Jun, 2026 | Gary Patou | Director | Disposed S | 1,322 | $53.14 | $70.25K | 24,896 | Direct |
| 01 Jun, 2026 | Steven Gannon | Director | Acquired M | 2,645 | — | — | 13,286 | Direct |
| 01 Jun, 2026 | Justin D. Gover | Director | Acquired M | 2,645 | — | — | 2,645 | Direct |
| 01 Jun, 2026 | Elizabeth A. Garofalo | Director | Acquired M | 2,645 | — | — | 2,645 | Direct |
| 01 Jun, 2026 | Dawn Svoronos | Director | Acquired M | 2,645 | — | — | 27,645 | Direct |
| 01 Jun, 2026 | Patrick Machado | Director | Acquired M | 2,645 | — | — | 2,645 | Direct |
| 01 Jun, 2026 | Gillian Cannon | Director | Acquired M | 2,645 | — | — | 2,645 | Direct |
| 01 Jun, 2026 | Gary Patou | Director | Acquired M | 2,645 | — | — | 26,218 | Direct |
| 01 Jun, 2026 | Dawn Svoronos | Director | Disposed F | 1,416 | $53.41 | $75.63K | 26,229 | Direct |
| 01 Jun, 2026 | Patrick Machado | Director | Disposed M | 2,645 | $0.00 | $0 | 0 | Direct |